M
MapLight Therapeutics, Inc. (MPLT)
NMS – Real vaqt narxi. Valyuta: USD
18.55
-0.68 (-3.54%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
18.55
0.00 (0.00%)
Bozordan keyin: Mar 27, 2026, 4:04 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NMS – Real vaqt narxi. Valyuta: USD
18.55
-0.68 (-3.54%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
18.55
0.00 (0.00%)
Bozordan keyin: Mar 27, 2026, 4:04 PM EDT
MapLight Therapeutics, Inc. nogironlikka olib keladigan markaziy asab tizimi kasalliklaridan aziyat chekayotgan bemorlar uchun klinik bosqichdagi biofarmatsevtika kompaniyasidir. Kompaniyaning mahsulotlari orasida shizofreniya va Altsgeymer kasalligining psixozini davolash uchun M 1 /M 4 muskarin agonisti bo'lgan ML-007C-MA; avtizm spektrining buzilishi belgisi bo'lgan ijtimoiy muloqotning etishmasligi va/yoki bezovtalikni davolash uchun ML-004; Parkinson kasalligida motor defitsitini davolash uchun ML-021; va giperaktivlik, impulsivlik va qo'zg'alish bilan bog'liq kasalliklarni davolash uchun G-protein bog'langan retseptor 52 musbat allosterik modulyatori bo'lgan ML-009 kiradi. Kompaniya, shuningdek, kasallikka sababchi bo'lgan neyronal davrlarni aniqlash va terapevtik modulyatsiya uchun ushbu davrlarga yo'naltirish platformasini ishlab chiqadi. MapLight Therapeutics, Inc. ilgari Alvarado Therapeutics, Inc. nomi bilan tanilgan va 2019 yil avgust oyida MapLight Therapeutics, Inc. nomini o'zgartirgan. MapLight Therapeutics, Inc. 2018 yilda tashkil etilgan va Redwood City, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Karl Deisseroth M.D., Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Dr. Karoly Nikolich Ph.D. | Founder |
| Dr. Robert C. Malenka M.D., Ph.D. | Co-Founder, Director & Member of Scientific Advisory Board |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-01-09 | 8-K | mplt-20260109.htm |
| 2025-12-04 | 8-K | mplt-20251204.htm |
| 2025-10-29 | 8-K | d89036d8k.htm |
| 2025-10-24 | 8-A12B | d48773d8a12b.htm |